Wegovy's Medicare price in 2026 is not one number. It ranges from $50 a month to $1,349 a month depending entirely on which of three payment pathways applies to your situation. Medicare added Wegovy coverage in two separate steps: first through Part D for the cardiovascular indication approved by the FDA in March 2024, then through the temporary Medicare GLP-1 Bridge program that started July 1, 2026. A third price, $385 a month, arrives January 1, 2027 through IRA drug price negotiation.
CoveredUSA breaks down exactly what you will pay under each Medicare pathway in 2026, what changes in 2027, and what Wegovy costs if none of the Medicare pathways apply to you. For the coverage-eligibility question rather than the price question, see does Medicare cover Wegovy.
Coverage Breakdown
Direct Answer: What Wegovy Costs on Medicare
It depends on your Medicare pathway. The GLP-1 Bridge charges a flat $50 a month from July 1, 2026 through December 31, 2027. Standard Part D for the cardiovascular indication charges normal plan cost sharing up to the $2,100 annual cap. Without either pathway, Wegovy's 2026 list price is $1,349 a month, dropping to a $385 negotiated price on January 1, 2027.
Three Prices, Three Pathways: The 2026 Wegovy Price Map
Medicare does not have a single Wegovy price in 2026 because Wegovy reached the market through two different regulatory doors. The Medicare Modernization Act of 2003 bars Part D from covering weight-loss drugs outright, so Medicare could not touch Wegovy until the FDA approved a non-weight-loss use. That happened in March 2024, when the FDA cleared Wegovy to reduce cardiovascular risk in people with established heart disease. CMS then layered a second, temporary pathway on top: the Medicare GLP-1 Bridge, effective July 1, 2026, which covers Wegovy for obesity alone at a flat copay.
Which price applies to you comes down to two questions: do you have a documented cardiovascular diagnosis, and does your BMI clear one of the Bridge program's three tiers? Answering both questions correctly, with your prescriber's help, determines whether you pay $50 a month, standard Part D cost sharing, or the full list price.
Medicare GLP-1 Bridge Price: $50 a Month Explained
Starting July 1, 2026, the Medicare GLP-1 Bridge charges a flat $50 a month for Wegovy, regardless of your plan's formulary tier or your income. CMS built the Bridge as a demonstration program that runs through December 31, 2027, and it is administered separately from standard Part D through the CMS contractor Humana. Your prescriber submits a prior authorization attesting that you meet one of three BMI tiers, and once approved, you pick up Wegovy at the pharmacy for $50.
The three qualifying tiers are BMI 35 or higher with no additional diagnosis required; BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3 or higher; or BMI 27 or higher with pre-diabetes, a prior heart attack or stroke, or peripheral artery disease. Low-Income Subsidy (Extra Help) does not reduce the $50 further; it is a flat rate for everyone the Bridge covers.
Standard Part D Price for the Cardiovascular Indication
Enrollees who qualify for Wegovy under the cardiovascular indication (established heart disease plus BMI 27 or higher) pay standard Part D cost sharing, not the flat Bridge rate. That means the 2026 Part D deductible of up to $615 applies first, then coinsurance or a copay set by your plan's formulary tier, until you reach the $2,100 annual out-of-pocket cap for covered Part D drugs. Once you hit $2,100 in true out-of-pocket spending for the year, covered Part D drugs cost you $0 for the rest of the calendar year.
Your exact monthly cost under this pathway depends on your plan: some Part D plans place Wegovy on a higher specialty tier with steeper coinsurance, while others negotiate a lower rate. Use the Medicare Plan Finder at medicare.gov to compare how different Part D plans price Wegovy on their formulary before you enroll or switch plans during Open Enrollment.
What Changes on January 1, 2027: The $385 Negotiated Price
Effective January 1, 2027, CMS's IRA Round 2 drug price negotiation sets a Maximum Fair Price of $385 a month for Wegovy, a 71% reduction from the 2026 list price of $1,349. That negotiated price replaces the list price for Medicare Part D billing purposes across all covered indications. Enrollees using the cardiovascular Part D pathway will see their plan cost sharing calculated against the lower $385 figure starting in 2027, which lowers coinsurance amounts even for people who have not yet hit the $2,100 cap.
CMS also planned a broader BALANCE Model to expand GLP-1 access through standard Part D plans at a negotiated $245 net price, but that Part D component was indefinitely delayed on April 21, 2026 after not enough plan sponsors signed on. The Bridge extension through December 31, 2027 now serves as the interim price mechanism for the obesity-only pathway while CMS figures out what comes next for Part D beyond 2027.
If Neither Pathway Applies: What Wegovy Costs Without Medicare Coverage
Medicare beneficiaries who lack a qualifying cardiovascular diagnosis and do not meet any of the three Bridge BMI tiers pay Wegovy's full 2026 list price of $1,349 a month unless they use a self-pay option. Alternatives exist, though they are more limited for Medicare enrollees than for commercially insured patients.
Does Original Medicare, Medicare Advantage, or Medigap Change the Price?
Original Medicare (Medicare Part A and Medicare Part B) does not price or cover Wegovy at all. Medicare Part A covers hospital stays and Medicare Part B covers physician-administered drugs and outpatient services; Wegovy is a self-injected outpatient prescription, so it falls entirely under Medicare Part D, whether standalone or bundled into a Medicare Advantage plan. If you have Original Medicare, you need a separate standalone Part D plan to access either the cardiovascular pathway or the GLP-1 Bridge.
Medicare Advantage plans that include drug coverage (MA-PD plans) can offer Wegovy at their own negotiated formulary price, which sometimes beats standard Part D pricing, and MA-PD plans participating in the Bridge can also offer the $50 copay. Medigap, by contrast, never touches drug pricing: Medigap policies only fill cost-sharing gaps in Medicare Part A and Medicare Part B (hospital and medical costs), and federal rules have excluded new Medigap drug benefits since 2006. If you carry Medigap, it has no effect whatsoever on what you pay for Wegovy.
Marketplace shoppers sometimes assume ACA-compliant plans handle weight-loss drugs the way they handle other essential health benefits, but anti-obesity medications are not one of the 10 required essential health benefits categories, so ACA marketplace plans can exclude Wegovy from their formulary just as Medicare's 2003 statute does. The one ACA protection that does carry over conceptually is that a preexisting condition, such as prior heart disease, cannot be used to deny you a Medicare Part D plan the way it once could in the individual market before 2014.
How to Confirm Your Exact Wegovy Price Before You Fill It
Because three different prices apply depending on your diagnosis and BMI, confirm your price before you go to the pharmacy rather than after. A few concrete steps prevent a surprise bill.
- Ask your prescriber which pathway they are billing under: the cardiovascular Part D indication or the GLP-1 Bridge. These use different prior authorization forms and different administrators.
- Call your Part D plan's member services line and ask for your Wegovy formulary tier and estimated cost sharing before your first fill.
- If billed under the Bridge, confirm your pharmacy is submitting the claim through the CMS contractor Humana, not your standard Part D plan, since misrouted claims are a common denial cause.
- Check the Medicare Plan Finder at medicare.gov during Open Enrollment (October 15 to December 7) to compare how different Part D and Medicare Advantage plans price Wegovy on their formularies for the coming year.
- If your claim is denied, request the denial in writing with the specific reason, then file a Part D appeal (redetermination) within 60 days; misapplied diagnosis codes are a common, fixable error.
Frequently Asked Questions
How much does Wegovy cost with Medicare Part D in 2026?
It depends on your pathway. Under the GLP-1 Bridge (July 2026 through December 2027), you pay a flat $50 a month. Under standard Part D for the cardiovascular indication, you pay your plan's normal cost sharing after the up-to-$615 deductible, capped at $2,100 a year. Without either pathway, Wegovy's 2026 list price is $1,349 a month.
Does the $50 Medicare GLP-1 Bridge copay count toward my Part D out-of-pocket cap?
No. The $50 monthly Bridge copay does not count toward the 2026 Part D annual out-of-pocket cap of $2,100 and does not count toward your Part D deductible. The Bridge operates as a separate CMS demonstration program outside the standard Part D benefit structure, administered by Humana.
What will Wegovy cost on Medicare after the IRA negotiated price starts?
Starting January 1, 2027, CMS's IRA Round 2 negotiation sets a Maximum Fair Price of $385 a month for Wegovy, replacing the $1,349 list price for Part D billing. That is a 71% reduction. Standard Part D cost sharing will then be calculated against the lower $385 figure instead of the list price.
What does Wegovy cost if Medicare does not cover it for me?
If you do not qualify for the cardiovascular Part D pathway or the GLP-1 Bridge, Wegovy's 2026 list price is $1,349 a month. Novo Nordisk's NovoCare Pharmacy offers a self-pay cash price of $349 a month for maintenance doses regardless of insurance status, which is available to Medicare beneficiaries even though the separate NovoCare Savings Card is not.
Does Medicare Advantage change the price of Wegovy?
It can. Medicare Advantage plans with drug coverage (MA-PD) set their own formulary tier and cost sharing for Wegovy, which sometimes differs from standalone Part D plans. MA-PD plans participating in the GLP-1 Bridge can also offer the $50 flat copay to enrollees who meet the BMI criteria.
Does Medigap lower my Wegovy Part D costs?
No. Medigap policies only cover cost-sharing gaps in Original Medicare Part A and Part B, such as hospital and physician cost sharing. Federal rules have excluded new Medigap drug coverage since 2006, so Medigap has no effect on your Wegovy price under Part D.
Can I use the NovoCare Savings Card with Medicare to lower the Wegovy price?
No. The NovoCare Savings Card is restricted to patients with commercial insurance and is explicitly not available to Medicare, Medicaid, or VA enrollees. If you have Medicare, your options are the $50 GLP-1 Bridge copay, standard Part D cost sharing, or the $349 NovoCare Pharmacy self-pay cash price.
Why are there two different Medicare prices for the same drug?
Wegovy reached Medicare coverage through two separate legal paths. The March 2024 FDA cardiovascular approval let standard Part D cover it under normal cost sharing. The 2003 weight-loss drug exclusion still blocks Part D from covering it for obesity alone, so CMS created the GLP-1 Bridge as a separate demonstration program with its own flat $50 price to reach that population instead.
